Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):374-81

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):374-81

LATEST ADVANCES IN RADIOPHARMACOLOGY AND RADIOPHARMACY 2009 

    REVIEWS

The use of imaging in preclinical drug development

Vanderheyden J. L.

GE Healthcare, Healthcare Systems, Molecular Imaging, Waukesha, WI, USA

Molecular imaging tools, both equipment and agents, continue to improve and evolve, offering multimodality imaging with greater sensitivity and high-resolution of biological processes in real time. This review summarizes some of these recent developments in preclinical hardware, wetware and software, and their impact on drug development. The focus is on the advances in non-invasive small animal imaging such as positron emission tomography (PET), computed tomography (CT) and solid state detectors in single photon emission tomography (SPECT), which, when combined with labeled tracers serving as biomarkers and functional probes in vivo, are demonstrating the potential to accelerate our understanding of disease and help select drug candidates for development.

language: English


FULL TEXT  REPRINTS

top of page